

- Karameris A. TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. *J Oral Pathol Med.* 2000;29:370-375.
31. Neppelberg E, Johannessen AC, Jonsson R. Apoptosis in oral lichen planus. *Eur J Oral Sci.* 2001; 109:361-364.
 32. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. *Nat Immunol.* 2004;5: 1219-1226.
 33. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. *Traffic.* 2002;3:710-717.
 34. Sozzani S. Dendritic cell trafficking: more than just chemokines. *Cytokine Growth Factor Rev.* 2005;16:581-592.
 35. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. *Nat Immunol.* 2004;5:1260-1265.
 36. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. *Annu Rev Immunol.* 2004;22:181-215.
 37. Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. *J Invest Dermatol.* 1997;109: 91-95.
 38. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. *Nat Med.* 1999;5:405-411.
 39. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. *Trends Immunol.* 2004;25:47-52.
 40. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force." *Blood.* 2005;106:2252-2258.
 41. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. *J Exp Med.* 2002;195:335-341.
 42. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. *J Exp Med.* 2002;195:343-351.
 43. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. *J Exp Med.* 2002;195:327-333.
 44. Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. *Eur J Immunol.* 2003;33:1657-1666.
 45. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. *Blood.* 2005;106:566-571.
 46. Sivori S, Falco M, Della Chiesa M, et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. *Proc Natl Acad Sci U S A.* 2004;101:10116-10121.
 47. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. *J Immunol.* 2005;174:727-734.
 48. Romagnani C, Della Chiesa M, Kohler S, et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4⁺ T helper cells and CD25^{hi} T regulatory cells. *Eur J Immunol.* 2005;35:2452-2458.
 49. Gerosa F, Tommasi M, Benati C, et al. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells. *Cell Immunol.* 1993;150:382-390.

Erratum

In the article by Nishimura et al entitled "Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo," which appeared in the March 1, 2007, issue of *Blood* (Volume 109:1992-1997), there were errors in the byline, the abstract, and the text. The third author's name should have been Adrian M. Piliponsky. Also, the abstract should have begun, "Plasma procarboxypeptidase B (proCPB) is activated by the endothelial thrombin-thrombomodulin complex. Activated proCPB (CPB) functions as" Finally, the last sentence of "Discussion" should have read, "Selective activation of thrombin, enhancing its antithrombotic and anti-inflammatory functions by combined activation of PC and proCPB, while minimizing its prothrombotic properties, may represent another avenue of developing new antithrombotic agents."⁴¹⁻⁴³ The byline error was corrected online in departure from print.